What triggered the tax-withholding share disposition reported by REGENXBIO (RGNX)?

The disposition was triggered by the vesting of restricted stock units originally granted to Steve Pakola on August 1, 2024 . When those RSUs vested on August 1, 2026, 7,468 shares were withheld to pay associated tax obligations.

REGENXBIO Inc. (RGNX) CMO has 7,468 shares withheld to cover RSU taxes

Q: Was the REGENXBIO (RGNX) Form 4 transaction a market sale of shares?

No. The Form 4 shows a tax-withholding disposition , where 7,468 shares were withheld by the company to satisfy tax liabilities from RSU vesting. It does not report an open-market purchase or sale initiated by the insider.

Q: At what price were REGENXBIO (RGNX) shares withheld for Steve Pakola’s taxes?

The 7,468 shares withheld for taxes were valued at $9.69 per share . This price was determined using the closing price of REGENXBIO’s common stock on August 1, 2026 , the date the restricted stock units vested and the taxes were satisfied.

Q: Was the REGENXBIO (RGNX) insider transaction made under a Rule 10b5-1 trading plan?

No. The Form 4’s Rule 10b5-1 checkbox is not marked, indicating the reported tax-withholding disposition was not designated as executed under a pre-arranged Rule 10b5-1 trading plan for Steve Pakola.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

REGENXBIO Inc. Chief Medical Officer Steve Pakola reported a tax-withholding disposition of 7,468 shares of common stock on August 1, 2026, at $9.69 per share. The shares were withheld to cover taxes on vesting restricted stock units granted August 1, 2024. He now directly holds 205,541 shares.

Insider Trade Summary

Net Seller: 7,468 shares

Net Sell 1 txn

Insider PAKOLA STEVE

Role Chief Medical Officer

Type	Security	Shares	Price	Value
Tax Withholding	Common Stock ^F1	7,468	$9.69	$72K

Holdings After Transaction: Common Stock — 205,541 shares (Direct)

Footnotes (1)

F1. Represents shares of common stock withheld to pay taxes upon the vesting of restricted stock units originally granted to the reporting person on August 1, 2024. The number of shares withheld was determined based on the closing price of the issuer's common stock on August 1, 2026.

Key Figures

Shares withheld for taxes: 7,468 shares Tax withholding price: $9.69 per share Shares held after transaction: 205,541 shares +1 more

4 metrics

Shares withheld for taxes 7,468 shares Common stock withheld on August 1, 2026 to pay RSU-related tax liability

Tax withholding price $9.69 per share Based on the closing price of REGENXBIO common stock on August 1, 2026

Shares held after transaction 205,541 shares Direct common stock ownership of Steve Pakola following the tax-withholding disposition

RSU grant date August 1, 2024 Original grant date of the restricted stock units that vested and triggered tax withholding

Key Terms

restricted stock units, withheld to pay taxes, closing price

3 terms

restricted stock units financial

"withheld to pay taxes upon the vesting of restricted stock units originally granted"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

withheld to pay taxes financial

"Represents shares of common stock withheld to pay taxes upon the vesting"

closing price financial

"determined based on the closing price of the issuer's common stock"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/04/2026 - 04:32 PM Accepted by SEC EDGAR 08/04/2026 - 04:30 PM

FAQ

What insider transaction did REGENXBIO (RGNX) report for Steve Pakola?

REGENXBIO (RGNX) reported that Chief Medical Officer Steve Pakola had 7,468 shares of common stock withheld on August 1, 2026 to pay taxes on vested restricted stock units. The withholding was priced at $9.69 per share, based on that day’s closing price.

Was the REGENXBIO (RGNX) Form 4 transaction a market sale of shares?

No. The Form 4 shows a tax-withholding disposition, where 7,468 shares were withheld by the company to satisfy tax liabilities from RSU vesting. It does not report an open-market purchase or sale initiated by the insider.

How many REGENXBIO (RGNX) shares does Steve Pakola hold after this transaction?

Following the tax withholding, Chief Medical Officer Steve Pakola directly holds 205,541 shares of REGENXBIO common stock. This figure reflects his direct ownership after 7,468 shares were withheld to cover taxes on the vesting restricted stock units.

At what price were REGENXBIO (RGNX) shares withheld for Steve Pakola’s taxes?

The 7,468 shares withheld for taxes were valued at $9.69 per share. This price was determined using the closing price of REGENXBIO’s common stock on August 1, 2026, the date the restricted stock units vested and the taxes were satisfied.

Was the REGENXBIO (RGNX) insider transaction made under a Rule 10b5-1 trading plan?

No. The Form 4’s Rule 10b5-1 checkbox is not marked, indicating the reported tax-withholding disposition was not designated as executed under a pre-arranged Rule 10b5-1 trading plan for Steve Pakola.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

PAKOLA STEVE

(Last)

(First)

(Middle)

C/O REGENXBIO INC.

9804 MEDICAL CENTER DRIVE

(Street)

ROCKVILLE

MARYLAND

20850

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
REGENXBIO Inc. [ RGNX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	08/01/2026		F		7,468⁽¹⁾	D	$9.69	205,541	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Represents shares of common stock withheld to pay taxes upon the vesting of restricted stock units originally granted to the reporting person on August 1, 2024. The number of shares withheld was determined based on the closing price of the issuer's common stock on August 1, 2026.

Remarks:

	/s/ Patrick J. Christmas as attorney-in-fact	08/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR